Skip to main content English


Lisa Gabler
Lisa Gabler, PhDPrincipal investigator

Department of Neurosurgery
Position: Research Associate (Postdoc)

ORCID: 0000-0002-6728-033X


Brain tumor biomarkers; Cell Communication; Embryonic Development; Molecular Targeted Therapy; Single-Cell Analysis

Research interests

I am a molecular biologist by training specializing in brain cancer research. I studied biomedical sciences, genetics, and molecular immunobiology at the University of Vienna and earned my Ph.D. in the lab of Prof. Walter Berger at the Center for Cancer Research Medical University of Vienna, focusing on biomarkers and targeted therapies for high-risk brain cancers. After completing my doctorate, I conducted my postdoctoral research in the Hovestadt lab at the Dana-Farber Cancer Institute in Boston, affiliated to the Harvard Medical School and the Broad Institute of MIT and Harvard. I was concentrating on computational science and precision medicine for brain cancer, specifically exploring cell-cell communication networks and receptor tyrosine kinases. I was recently awarded the APART-MINT, and the ESPRIT scholarships of the Austrian Academy of Sciences and the Austrian Science Fund, respectively, enabling me to fill a scientific gap Department of Neurosurgery, Medical University of Vienna, in July 2023. I aim at continuing my research on therapeutic applications for cell-cell communication networks in aggressive cancers.

Techniques, methods & infrastructure

omics-based analyses (scRNAseq, bulk RNA seq, WGS, WES, expression arrays), patient-derived cancer cell models, stem cells, cell-communication, stimulation/inhibition assays, viral vector design, cloning, barcoding, therapeutic and genetic target inhibition, genetic engineering

Selected publications

  1. Gabler, L. et al. (2022) ‘Fibroblast growth factor receptor 4 promotes glioblastoma progression: a central role of integrin-mediated cell invasiveness’, Acta Neuropathologica Communications, 10(1). Available at:
  2. Gabler, L. et al. (2019) ‘TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAFV600E/TERT promoter double-mutated glioma’, Acta Neuropathologica Communications, 7(1). Available at:
  3. Lötsch, D. et al. (2021) ‘Targeting fibroblast growth factor receptors to combat aggressive ependymoma’, Acta Neuropathologica [Preprint]. Available at:
  4. Pirker, C. et al. (2020) ‘Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup’, Clinical Cancer Research, 26(14), pp. 3819–3830. Available at:
  5. Englinger, B. et al. (2017) ‘Intrinsic fluorescence of the clinically approved multikinase inhibitor nintedanib reveals lysosomal sequestration as resistance mechanism in FGFR-driven lung cancer’, Journal of Experimental & Clinical Cancer Research, 36(1). Available at: